Took a look at the swamp so that you don't have to
Post# of 72447
(Total Views: 543)
Posted On: 04/16/2017 8:31:04 PM
Took a look at the swamp so that you don't have to ruin any nice holiday and/or weekend feelings you may have.
They are outdoing themselves with ridiculous lies and FUD.
First of all, Passover does not mean that Leo Ehrlich takes 8 days off. He has a nice, lengthy dinner with family and friends on 2 nights (last Monday and Tuesday). Anyone really think that's going to "keep him busy" for 8 days? Absurd. It's as silly as saying that a religious Christian can't get any work done during Holy Week.
Second of all, CTIX has been very forthcoming, that the Brilacidin-ABSSSI test would be incredibly expensive -- tens of millions of dollars -- so they decided to put it on the back burner while they went incredibly quickly on the much shorter, much less expensive clinical trials that will yield results in a short period of time. That's why the focus is on Brilacidin-OM, Brilacidin-UP, and Prurisol. The fact that they've started the Kevetrin trial for ovarian cancer is an unexpected (to me) bonus.
The desperation of the handful of names posting FUD over there, which is to say 2 or 3 people under multiple identities, is actually reassuring. They are really scared of the stock price moving up this week. When they are scared, I feel happy.
They are outdoing themselves with ridiculous lies and FUD.
First of all, Passover does not mean that Leo Ehrlich takes 8 days off. He has a nice, lengthy dinner with family and friends on 2 nights (last Monday and Tuesday). Anyone really think that's going to "keep him busy" for 8 days? Absurd. It's as silly as saying that a religious Christian can't get any work done during Holy Week.
Second of all, CTIX has been very forthcoming, that the Brilacidin-ABSSSI test would be incredibly expensive -- tens of millions of dollars -- so they decided to put it on the back burner while they went incredibly quickly on the much shorter, much less expensive clinical trials that will yield results in a short period of time. That's why the focus is on Brilacidin-OM, Brilacidin-UP, and Prurisol. The fact that they've started the Kevetrin trial for ovarian cancer is an unexpected (to me) bonus.
The desperation of the handful of names posting FUD over there, which is to say 2 or 3 people under multiple identities, is actually reassuring. They are really scared of the stock price moving up this week. When they are scared, I feel happy.
(2)
(0)